

S 3401

ABC Safe Drug Act

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Dec 15, 2021

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Dec 15, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/3401>

Sponsor

Name: Sen. Cotton, Tom [R-AR]

Party: Republican • State: AR • Chamber: Senate

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Braun, Mike [R-IN]	R · IN		Dec 15, 2021

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Dec 15, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 7121	Related bill	Mar 28, 2022: Referred to the Subcommittee on Health.
117 S 2495	Related bill	Jul 28, 2021: Read twice and referred to the Committee on Finance.

Anyone But China Safe Drug Act or the ABC Safe Drug Act

This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing ingredients manufactured in China, and requires drugs to be labeled for country of origin.

The Food and Drug Administration shall maintain (1) a list of foreign-sourced drugs and active ingredients that are critical for consumer health and safety, and (2) another list identifying such drugs that are produced exclusively in China or use ingredients produced in China.

The bill phases in a restriction on federal health care programs purchasing drugs with active ingredients manufactured in China. By January 1, 2026, such programs may not purchase a drug with any active ingredients from China. The Department of Health and Human Services may issue a waiver for an agency or program that is unable to meet this requirement, but no waiver may apply to drugs purchased in or after 2027.

Each drug must have labeling listing the country of origin of each active ingredient, and a drug without this labeling shall be deemed misbranded.

Actions Timeline

- **Dec 15, 2021:** Introduced in Senate
- **Dec 15, 2021:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.